Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HER2-expressing Cancers Clear all
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 22, 2026, 3:50 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
HMPL-A251
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Plantation, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW49
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced May 22, 2026, 3:50 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions
ORM-5029
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Colorectal Neoplasm
Interventions
DS-8201a
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HER2 Expressing Breast or Gastric/Stomach Cancers
Interventions
MEDI4276
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Stanford, California • Sarasota, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm
Interventions
TAK-165
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HER2 Expressing Solid Tumors
Interventions
ADXS31-164
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Urothelial Carcinoma
Interventions
Trastuzumab deruxtecan, Nivolumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Interventions
CDX-011, Capecitabine
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
71
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox, flow cytometry, immunoenzyme technique
Drug · Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced May 22, 2026, 3:50 AM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Gastric/Gastroesophageal Junction Cancer
Interventions
KN026
Drug
Lead sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Interventions
ACE1702, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced May 22, 2026, 3:50 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Olaparib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 3:50 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HER2 Expressing Solid Tumors
Interventions
Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202, Dose Level 4, VNX-202
Genetic
Lead sponsor
Vironexis Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 22, 2026, 3:50 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
Interventions
BL-M17D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced May 22, 2026, 3:50 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Trastuzumab Deruxtecan, Bevacizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
24
States / cities
La Jolla, California • Fort Lauderdale, Florida • Jupiter, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Miami, Florida • Chicago, Illinois • Zion, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced May 22, 2026, 3:50 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Neoplasm Malignant, Breast Cancer, Lung Neoplasm Malignant, Gastric Cancer, Neoplasm
Interventions
SAR443216 IV, SAR443216 SC
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced May 22, 2026, 3:50 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
89
States / cities
Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced/Metastatic HER2 Positive Solid Tumors
Interventions
BB-1701
Drug
Lead sponsor
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
San Francisco, California • Nashville, Tennessee • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced May 22, 2026, 3:50 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumors
Interventions
Runimotamab, Trastuzumab, Tocilizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
New Haven, Connecticut • Saint Louis, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 22, 2026, 3:50 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression
Interventions
ACTR T Cell Product
Other
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim
Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced May 22, 2026, 3:50 AM EDT